PRESSR: Align Technology unveils new Invisalign palatal expander ahead of 37th International Dental CAD/CAM ConfEx

For Immediate Release

Chicago, IL – October 31, 2024 – Zacks Equity Research shares Boot Barn BOOT as the Bull of the Day and Align Technology ALGN as the Bear of the Day. In addition, Zacks Equity Research provides analysis on GameStop Corp. GME, Best Buy Co., Inc. BBY and Sony Group Corp. SONY.

Here is a synopsis of all five stocks:

Bull of the Day:

Boot Barn is a Zack Rank #1 (Strong Buy) that is a leading lifestyle retail chain in the United States, focusing on western and work-related footwear, apparel, and accessories.

The company just reported an earnings beat, only to see the stock fall 20% since the report. While the move lower could simply be profit taking, news that the CEO is leaving accelerated the selling.

Investors are now looking at a long-term opportunity as the selling gets closer to support levels and earnings estimates head higher.

About the Company

Boot Barn has a market cap of $4 billion and the company employs over 11,000, including 3,100 full-time employees.

Founded in 1978 and headquartered in Irvine, California, the company operates over 420 stores across 46 states, offering a wide range of products including boots, shirts, jackets, hats, and rugged workwear for men, women, and children. In addition to its physical stores, Boot Barn also has a strong online presence, allowing customers to shop through its e-commerce websites like BootBarn.com, Sheplers.com, and CountryOutfitter.com

The stock has Zacks Style Scores of "A" in Momentum and "B" in both Value and Growth.

Q2 Earnings

On October 28th, Boot Barn reported Q2 earnings, beating estimates by 2%. Revenues came in slightly above expectations and the company raised its FY25 guidance. Boot Barn raised FY25 to a range $5.30-5.60 v the $5.38 expected, and sees Same Store Sales (SSS) at 3.0-5.0% v the prior -1% to +1.2%.

While next year looks positive, BOOT now sees Q3 at $1.96-2.07 v the $2.09 expected. So short term there was a little disappointment, which caused some selling after the earnings release.

More highlights from the earnings report include SSS up 4.9% y/y and affirming FY25 Capex. This includes the goal to open 60 new stores.

CEO Leaving

The stock traded lower by about 18% after the earnings release. But this wasn't just because of a disappointment in earnings, it was also because long-term CEO Jim Conroy is leaving to join Ross Stores in November. Conroy, who has led Boot Barn for over a decade, oversaw significant growth, including the company going public. So, investors that were big fans, might have decided to take some profits.

John Hazen, Boot Barn's current chief digital officer, will serve as interim CEO while the company searches for a permanent replacement.

Estimates Headed Higher

Typically, when we see a big move lower in a stock, the estimates are going lower. However, the CEO departure might have overshadowed the fact that estimates are going higher.

Since earnings, the current quarter has remained the same, at $2.09. Looking at next quarter we see the move in earnings estimates go from $1.15 to $1.18, or 3%.

For the current year, numbers have gone from $5.38 to $5.43

Next year, analysts are looking for $6.53, up from negative $6.47 prior to the earnings report.

To summarize, we have negative price reaction into short term stalling of growth and a CEO departure. And because the stock was up over 100% in 2024, profit taking has commenced.

However, analysts have kept price targets significantly above current trading levels.

Baird raised BOOT to an Outperform, with a target at $167, saying investors have a more favorable setup following pullback.

Benchmark reiterated its Buy and $192 target, while Citigroup lowered their target to $178.

These price targets give us a range of 30-50% above current trading levels.

The Technical Take

While those price targets look tempting to investors, a good entry point into the selling is critical. Let us look at some moving averages:

The 200-day moving average is at $118.65.

The 21-day MA is $159.

The 50-day is $154.50.

The 61.8% Fibonacci level drawn from the 2024 lows to highs is $109, while the halfway back is $120. This creates a solid buy zone just below the 200-day MA.

If Boot Barn can maintain its strong fundamental record, the selling should run into support and the stock will see a solid rally to those MA resistance levels above $150.

In Summary

Boot Barn faces short-term challenges with the departure of CEO Jim Conroy and a subsequent drop in stock price. However, the company's strong fundamentals and optimistic outlook provide a solid foundation for potential recovery.

Analysts remain bullish, with several raising their price targets significantly above current trading levels, indicating confidence in Boot Barn's growth trajectory.

As the company navigates this transition, maintaining its robust performance will be crucial for regaining investor confidence and capitalizing on its strong market position. Investors may find strategic entry points as the stock stabilizes, setting the stage for future gains.

Bear of the Day:

Align Technology is a Zacks Rank #5 (Strong Sell) that is a global leader in digital orthodontics and the creator of the Invisalign clear aligner system.

Align recently reported earnings, with an initial negative price reaction turning positive. However, the stock has already drifted lower and with price near 2024 lows, investors have a tough choice to make if the downward trend continues.

Unfortunately, the company faces bearish growth prospects as its forward-looking guidance indicates cautious expectations for the U.S. market. Additionally, anticipated flat to slightly increasing revenues in Q4 2024 are raising concerns about the sustainability of its growth trajectory.

About the Company

Founded in 1997 and headquartered in Tempe, Arizona, the company focuses on developing innovative products and technologies that enhance the practice of dentistry.

Align is valued at $16 billion and has a Forward PE of 22. The stock holds Zacks Style Scores of "B" in Growth, but "F" in Value and "D" in Momentum. The stock pays no dividend.

Q3 Earnings

Align reported Q3 EPS of $2.35, surpassing the expected $2.31. However, revenue fell short, coming in at $977.9 million compared to the anticipated $991 million.

For Q4, the company has provided lower guidance, projecting revenue between $955 million and $1.02 billion, slightly below the expected $1.02 billion.

Case shipments increased to 617.2K, up from 602K year-over-year, while the non-GAAP operating margin improved to 22.1%, compared to 21.8% in the same period last year.

In light of these results, the company stated that it continues to evaluate and evolve its business to provide doctors with the best tools and resources while managing operational challenges.

Earnings Estimates

Looking at estimates, analysts have already started to cut their numbers for most time frames.

For the current quarter, analysts have lowered estimates from $2.55 to $2.45 since EPS. This is a drop of 4%.

Next quarter estimates see a slight uptick, but when you look down the road, the numbers take a negative turn.

For the current year, estimates have dropped from $9.36 to $9.29 since the earnings report.

Next year shows a bigger trend to the downside when you look over the last 90 days. Estimates have dropped from $10.51 to $10.15, or 3.4%, including another 1.2% since earnings.

Technical Take

The stock has been on a steady downtrend since March of 2024 when it traded as high at $335. Since then, ALGN is lower by 35%.

The prior 2024 lows are $196 so a break below the $200 level could signal trouble. Weaker hands likely have stop orders below that prior low and the next support level is not seen until $172 and then the COVID low is $127.

To the upside, the 50-day MA is $232 and the 200-day MA is $263. Until those levels are taken back by the bulls, the bears have control.

In Summary

Align is navigating a challenging landscape, marked by bearish growth prospects and a lackluster revenue outlook. While the company's recent earnings report showcased some positive metrics, including an EPS beat and improved case shipments, the underlying trends paint a concerning picture for investors.

Additional content:

Trading at a Discount, Is GameStop Still in the Game?

GameStop Corp., the original "meme stock" that ignited a social media-fueled trading frenzy, is now sitting at a significant discount compared to its previous highs. Once the favorite of retail investors and Reddit forums, GameStop has recently slipped in value, tempting bargain hunters and seasoned investors alike to take a second look. But is GameStop's discounted price an opportunity or just another chapter in a volatile saga?

The video game retailer is currently trading at a forward 12-month price-to-sales (P/S) multiple of 2.56X, which positions it at a discount compared to the industry's average of 2.91X. The stock has also been trading below the high level of 4.16, as observed over the past five years.

However, shares of GameStop have just risen 0.1% in the past three months compared with the industry's growth of 5.6%. Moreover, GME has underperformed the broader Zacks Consumer Discretionary sector and the S&P 500's respective gains of 6.8% and 5.3% in the same time frame. The sluggish price movement reflects underlying challenges that could be impacting investor sentiment.

GameStop stock closed at $22.68 during yesterday's trading session, sitting 65% below its 52-week high of $64.83, achieved on May 14, 2024. The stock is trading above both its 50-day and 200-day moving averages, indicating robust upward momentum and price stability.

Is GameStop Still in the Game?

GameStop maintains a loyal following among retail investors, sustaining its status as a meme stock. The company has seen increased interest from institutional investors. This shift indicates a growing recognition of GameStop's potential beyond its meme stock identity. Institutional buying could provide additional support to the stock, helping stabilize prices and enhance credibility in the eyes of retail investors.

GameStop's business model is undergoing significant transformation. The company is steadily shifting toward becoming a more digital-centric entity. GameStop is leveraging the shift toward digital commerce with an increased focus on e-commerce and digital gaming. This transition is critical, especially as consumer shopping habits evolve, making it essential for GameStop to capitalize on the digital marketplace.

Another positive aspect is GameStop's improving balance sheet. As of the end of the second quarter of fiscal 2024, the company reported cash, cash equivalents and marketable securities totaling $4.2 billion. This strengthened cash position, combined with reduced debt, provides a solid financial foundation that enables GameStop to pursue strategic investments without excessive leverage. Furthermore, the recent completion of its "at-the-market" equity offering program, which involved selling a maximum of 20 million shares for approximately $400 million in gross proceeds, will support acquisitions and other investment opportunities.

GameStop's collaborations with industry leaders in the gaming and technology sectors position it for future growth. The company's focus on innovative technologies and expanding its offerings in collectibles and merchandise indicates a commitment to diversifying its revenue sources and engaging a wider audience.

Still an Uphill Task for GameStop?

Despite these positive developments, several factors have contributed to a recent slowdown in GameStop's stock momentum. Market corrections, changing investor sentiment and broader economic pressures have all played a role. As enthusiasm waned and trading volumes normalized, the stock retreated from its previous highs. Investor scrutiny has intensified due to ongoing concerns about the company's strategic direction and ability to navigate the rapidly evolving gaming industry.

The gaming industry has been experiencing a rapid shift from physical game purchases to digital downloads, which challenges GameStop's traditional business model. As more consumers opt to buy games online through digital platforms, GameStop's reliance on physical sales could impact revenue growth. This shift is compounded by an increasing number of gamers embracing subscription services, diminishing the demand for physical copies of games.

GameStop reported a sharp decline in net sales for the second quarter of fiscal 2024, reaching $798 million, down from $1,163.8 million in the same period last year. This 31.4% year-over-year fall suggests a potential struggle to retain market share and indicates waning demand for GameStop's products amid a rapidly changing gaming landscape.

Sales across key segments — hardware and accessories, software and collectibles — experienced notable declines of 24.4%, 47.7% and 17.9%, respectively.

GameStop faces competition from Best Buy Co., Inc. and Sony Group Corp.. These competitors have a stronghold on digital game sales and subscriptions, making it challenging for GameStop to maintain market share.

What Should Be Your Strategy for GME?

GameStop stands at a critical juncture, marked by potential and risk. The company's shift toward a more digital-focused business model and improved financial position indicate a proactive response to evolving market demands. However, the notable decline in sales and intense competition from industry giants underscore the challenges it faces.

As GameStop works to redefine its identity beyond its meme stock status, investors must weigh the possibilities for recovery against the risks presented by a changing gaming landscape. Long-term investors are advised to hold their positions while closely monitoring the company's progress. Meanwhile, new investors should exercise caution. GME currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Why Haven't You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

https://www.zacks.com

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.

Zacks Investment Research

Align Technology (ALGN) is a Zacks Rank #5 (Strong Sell) that is a global leader in digital orthodontics and the creator of the Invisalign clear aligner system.

Align recently reported earnings, with an initial negative price reaction turning positive. However, the stock has already drifted lower and with price near 2024 lows, investors have a tough choice to make if the downward trend continues.

Unfortunately, the company faces bearish growth prospects as its forward-looking guidance indicates cautious expectations for the U.S. market. Additionally, anticipated flat to slightly increasing revenues in Q4 2024 are raising concerns about the sustainability of its growth trajectory.

About the Company

Founded in 1997 and headquartered in Tempe, Arizona, the company focuses on developing innovative products and technologies that enhance the practice of dentistry.

Align is valued at $16 billion and has a Forward PE of 22. The stock holds Zacks Style Scores of “B” in Growth, but “F” in Value and “D” in Momentum. The stock pays no dividend.

Q3 Earnings

Align reported Q3 EPS of $2.35, surpassing the expected $2.31. However, revenue fell short, coming in at $977.9 million compared to the anticipated $991 million.

For Q4, the company has provided lower guidance, projecting revenue between $955 million and $1.02 billion, slightly below the expected $1.02 billion.

Case shipments increased to 617.2K, up from 602K year-over-year, while the non-GAAP operating margin improved to 22.1%, compared to 21.8% in the same period last year.

In light of these results, the company stated that it continues to evaluate and evolve its business to provide doctors with the best tools and resources while managing operational challenges.

Earnings Estimates

Looking at estimates, analysts have already started to cut their numbers for most time frames.

For the current quarter, analysts have lowered estimates from $2.55 to $2.45 since EPS. This is a drop of 4%.

Next quarter estimates see a slight uptick, but when you look down the road, the numbers take a negative turn.

For the current year, estimates have dropped from $9.36 to $9.29 since the earnings report.

Next year shows a bigger trend to the downside when you look over the last 90 days. Estimates have dropped from $10.51 to $10.15, or 3.4%, including another 1.2% since earnings.

Technical Take

The stock has been on a steady downtrend since March of 2024 when it traded as high at $335. Since then, ALGN is lower by 35%.

The prior 2024 lows are $196 so a break below the $200 level could signal trouble. Weaker hands likely have stop orders below that prior low and the next support level is not seen until $172 and then the COVID low is $127.

To the upside, the 50-day MA is $232 and the 200-day MA is $263. Until those levels are taken back by the bulls, the bears have control.

In Summary

Align Technology (ALGN) is navigating a challenging landscape, marked by bearish growth prospects and a lackluster revenue outlook. While the company's recent earnings report showcased some positive metrics, including an EPS beat and improved case shipments, the underlying trends paint a concerning picture for investors.

For those interested in the Medical Supply space, a better option might be Becton, Dickinson and Company (BDX). The stock is a Zacks Rank #2 (Buy) that is coming off a 6% EPS beat.

Zacks Investment Research

Former President Donald Trump previously spent four years in the White House, which could help investors know which stocks and sectors could benefit under a second term if he wins the 2024 presidential election.

Here's a look back at the top performing stocks in 2017, Trump's first year in the White House.

Top Performing 2017 Stocks: The stock markets saw impressive gains in 2017, which were among the best ever for a president's first year in the White House.

The S&P 500, which is tracked by the SPDR S&P 500 ETF Trust , gained 21.7% in 2017, an impressive gain to the +12.0% increase in 2016, as presidential election years have historically produced outperformance to other years.

With the potential for Trump to be re-elected in 2024, here's a look back at the top 10 performing stocks in the S&P 500 from 2017, as reported previously by Marketwatch.

• NRG Energy : +132%, utilities
• Align Technology : +131%, health care
• Vertex Pharmaceuticals : +103%, health care
• Wynn Resorts : +95%, consumer discretionary
• Boeing Co : +89%, industrials
• Micron Technology : +88%, technology
• D.R. Horton : +87%, consumer discretionary, homebuilders
• PayPal Holdings : +87%, technology
• NVIDIA Corporation : +81%, technology
• Pulte Group : 81%, consumer discretionary, homebuilders

The top 10 stocks in 2017 likely saw gains related to reasons that didn't have to do with Trump being president, but there are also some common themes and some potential connections to the former president.

The results show that health care, consumer discretionary and technology stocks were among the top-performing sectors.

Of particular note is Micron and Nvidia, both ranking in the top 10, a potential positive for the semiconductor sector under a Trump presidency.

Another key trend could be two homebuilders ranking among the top 10 best-performing stocks in 2017. Homebuilders have been a popular sector to watch under a possible Kamala Harris win with the current vice president and Trump running on a platform of building more homes for the middle class.

Did You Know?

• Congress Is Making Huge Investments. Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool

Why It's Important: While past results don't guarantee future results, sometimes market trends can show patterns and signs of what to come.

Based on the top-performing stocks in 2017, investors may want to prepare for some exposure to health care, utilities, semiconductors and homebuilders if Trump wins the 2024 election.

With less than two weeks until the 2024 election, investors are likely positioning their portfolios based on a Trump or Harris win in some regards. With a close election predicted, investors may want to look to sectors that could benefit under either candidate.

Freedom Capital Markets Chief Global Strategist Jay Woods previously shared some sectors and stocks to watch with Benzinga that could benefit regardless of whether Trump or Harris wins the 2024 election.

Woods named defense stocks and cybersecurity stocks as two of the top sectors to watch ahead of the 2024 election.

"I think you've got to watch this sector closely," Woods said of the defense sector.

Woods said defense stocks could continue to benefit from geopolitical concerns and a lot of bad things happening in the world.

Read Next:

• If Trump Wins 2024 Election In Landslide, Bettors Could Make 5X, 20X Their Bets At UK Sportsbook

Photo: Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Align Technology, Inc. ALGN recently announced the release of the next version of Invisalign Smile Architect software. The software now supports Multiple Treatment Plans, which is likely to allow doctors to visually compare and modify orthodontic only and ortho restorative treatment plans side-by-side.

The Multiple Treatment Plans are integrated into ClinCheck treatment planning software which allows doctors to visually compare, review, and choose the best treatment option for each patient.

Likely Trend of ALGN Stock Following the News

Following the announcement, shares of the company moved nearly 1.1% north to $219.3 at Friday’s close. For the year-to-date period, ALGN shares have declined 19% compared with the industry’s fall of 0.7%. The S&P 500 increased 21.9% in the same time frame.

Meanwhile, ALGN currently has a market capitalization of $16.38 billion. In the last reported quarter, ALGN delivered an earnings surprise of 1.7%.

More on ALGN’s Invisalign Smile Architect Software

With the help of the Invisalign Smile Architect ortho restorative software, which features a tooth mass analysis tool that shows minimal tooth reduction, dentists can combine the advantages of the Invisalign System with restorative treatment to offer their patients a range of treatment options to transform their individual smiles.

A physician can use an iTero scanner to visually demonstrate ortho-only and ortho-restorative treatment simulations during an in-office visit. They can also submit patient records to be used with Invisalign Smile Architect's features to create a customized ClinCheck treatment plan for their patient, whether it is ortho-restorative or ortho-only.

The newly released software is compatible with the Align Digital Platform, a special set of programs, systems, and services created by Align Technology to offer a smooth workflow and experience that unifies and connects all users, including physicians, labs, patients, and customers. Flex Rx, Invisalign Personalized Plan, ClinCheck Smile Video, and ClinCheck Live Update are among the new features it offers. It provides a single ecosystem for combined visual orthodontic and restorative treatment planning, including facial lines, tooth mass analysis, and in-face displays.

Invisalign Smile Architect software with Multiple Treatment Plans is expected to be available to Invisalign-trained doctors in the fourth quarter of 2024

More on ALGN’s Invisalign Business Expansion

Align Technology continues to receive positive feedback for the Invisalign Palatal Expander System, and through the third quarter of 2024, Align Technology successfully continued to commercialize this device. In October, the company announced Palatal Expander System’s commercial availability in Singapore and expects to extend the availability of the transformative Invisalign Palatal Expander System to even more doctors and their patients in markets across the Asia Pacific region.

Further, the company is gaining in terms of strong adoption of Vivera retainers ordered through the DSP, as well as clinical training and education accessories in eCommerce. The company has also progressed with the Invisalign DSP touchup cases during the third quarter, up nearly 30% year over year to more than 25,000 cases.

The company has extended DSP into more countries in Europe and currently anticipates expanding into additional markets going forward. Align Technology has also established relationships in many DSOs globally to help drive the adoption of digital technology across the dental industry. Smile Docs and Heartland Dental are two of the company’s largest DSO partners at present.

Favorable Industry Prospects for ALGN

Per a report by Fortune Business Insights, the global clear aligners market size was valued at $3.80 billion in 2023 and is expected to reach beyond $28.15 billion by 2032, exhibiting a CAGR of 25.2%.

Technological advancements, such as computer-aided design and manufacturing, allow for the precise fabrication of aligners, resulting in better treatment outcomes. These factors contribute to the market growth. Moreover, dental education and infrastructure in dental space are increasing rapidly, which is expected to drive the market in the future. 

AngioDynamics’ Zacks Rank & Stocks to Consider

ALGN carries a Zacks Rank #4 (Sell) at present.

Some better-ranked stocks in the broader medical space are Addus HomeCare ADUS, Quest Diagnostics DGX and RadNet RDNT. While Addus HomeCare sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and RadNet carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Addus HomeCare has an estimated long-term growth rate of 12.1%. ADUS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 11.5%.

Addus HomeCare shares have rallied 85.5% compared with the industry's 16.9% growth year to date.

Quest Diagnostics has an estimated long-term growth rate of 6.8%. DGX's earnings surpassed estimates in each of the trailing four quarters, with the average being 3.3%.

Quest Diagnostics has gained 42% compared with the industry's 14.9% growth year to date.

RadNet’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 98.2%.

RDNT's shares have surged 93.7% year to date compared with the industry’s 14.8% growth.

Zacks Investment Research

• Events took place across Dubai, Kuwait, Jeddah, and Riyadh from September 26–27, 2024.
• 158 regional dental professionals attended in-person sessions led by top orthodontic experts.
• This was the third in a four-part series aimed at helping dental professionals enhance clinical outcomes, expand their patient base, and adopt Align Technology’s digital workflow.

Dubai, United Arab Emirates – Align Technology, Inc. (“Align”) a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, has successfully completed the third step of its Growing Patients Roadshow in the Middle East.

The third in a four-part series of educational roadshows to advance digital transformation for Middle East dentists was held on the 26th and 27th of September across Dubai, Kuwait, Jeddah, and Riyadh. The series of events focused on the 'Enhance' phase, aimed at improving clinical outcomes for growing patients through innovative treatment solutions.

More than 150 dental professionals from across the region had the opportunity to hear from experts, including Dr. Roelien Stapelberg in Dubai, Dr. Dalal Rashidi in Kuwait, Dr. Osama Basri in Jeddah, and Dr. Ibrahim Alshahrani in Riyadh, as they shared insights on how to elevate orthodontic skills and enhance patient care.

Each session offered in-depth insights into leveraging the Align™ Digital Platform (ADP) to enhance treatment planning and clinical outcomes for young patients. The sessions also focused on the use of ClinCheck® Software and other ADP tools, providing participants with practical knowledge to optimize their Invisalign® treatments for teens and younger patients, following the publication of Align Technology’s research into treating Growing Patients earlier this year.

Angelo Maura, General Manager Middle East, Align Technology, expressed his enthusiasm for the success of the event. “The Growing Patients Roadshow is a testament to our commitment to supporting dental professionals across the region. With over 18.2 million Invisalign® patients treated globally, including 5 million teens, the Growing Patients initiative is one of our key strategic pillars. By empowering orthodontists with the latest digital tools and treatment strategies, we can help them provide superior care to their younger patients, ensuring better clinical outcomes and a more streamlined workflow for their practices.”

Throughout the event, dental professionals gained a valuable understanding of how to navigate growing patient cases by utilising digital tools that streamline the treatment process and enhance patient experiences. The roadshow sessions also provided expert guidance on troubleshooting common challenges associated with Invisalign® treatments for younger patients, offering practical solutions that help improve both clinical outcomes and patient compliance.

As Align Technology continues its mission to transform the way dental professionals approach growing patient treatments, the company remains focused on providing the tools and knowledge necessary to achieve long-lasting results for both practitioners and their young patients. The roadshow is part of a broader effort to advance digital orthodontics across the Middle East, with the event culminating in December with the fourth and final Growing Patients Roadshow event of 2024, welcoming guest speaker Dr Sandra Tai.

For more information about the Growing Patients Roadshow and Align Technology’s range of innovative products, visit https://align.digitalplatform.me/growing-patients-roadshow.

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 266 thousand doctor customers and is key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 27 years, Align has helped doctors treat over 18.2 million patients with the Invisalign system and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.